Sarepta Therapeutics (SRPT) shares have surged in trading today amid speculation that the FDA may approve its DMD drug. Investors have turned bullish on SRPT amid reports hat eteplirsen reviewer Ron Farkas has left the agency. He was the most direct in his opinion that the company had not submitted sufficient data to prove the efficacy of eteplirsen for the treatment of Duchenne muscular dystrophy.